Views: 856

Community Reach: Community-Based Screening Program for Hepatitis C Among People Who Use Drugs, Arizona

Cassidy Snyder1, Karen Broman2, Beth E. Meyerson3,*, Tripti Choudhury4, Joby De La Rosa5, Roberto C. Garcia6, Angelica Garcia Lizarraga7, Steven Levin8, Deseree Sieloff9, Rachael Sweet10, Turiya Weiss11, Courteney Wettemann12, Dusti Yamaguchi13

1Preskitt Needle Exchange

2Sonoran Prevention Works Prescott, Arizona

3University of Arizona Southwest Institute for Research on Women (SIROW) 925 N. Tyndall Avenue, Ste 201 Tucson, Arizona

4AZ Recovery Advocacy Project Mesa, Arizona

5Church of Safe Injection Tucson Tucson, Arizona

6Sonoran Prevention Works Yuma, Arizona

7Sonoran Prevention Works Phoenix, Arizona

8Sonoran Prevention Works Phoenix, Arizona

9Sonoran Prevention Works Globe, Arizona

10Kingman Harm Reduction Program, Sonoran Prevention Works Kingman, Arizona

11Less Harm Consulting Prescott, Arizona

12Hepatitis Education Project Seattle, Washington

13Kingman Harm Reduction Program Sonoran Prevention Works Kingman, Arizona

*Corresponding Author: Beth E. Meyerson, PhD, University of Arizona Southwest Institute for Research on Women (SIROW) 925 N. Tyndall Avenue, Ste 201 Tucson, Arizona, Email: bmeyerson@arizona.edu

Received date: 07 October, 2022              Accepted date: 31 October, 2022                 Published Date: 14 November, 2022

Citation: Snyder C, Broman K, Meyerson E, Choudhury T, Rosa J, et al. (2022) Community Reach: Community-Based Screening Program for Hepatitis C Among People Who Use Drugs, Arizona. Sci J Health Sci Res Vol: 1, Issu: 2 (74-80).

Copyright: © 2022 Meyerson E, et al.

Abstract

Introduction: Efforts to eliminate hepatitis C are hampered by the inability to reach communities with screening opportunities, especially people who use drugs. The purpose of this study is to evaluate the feasibility and impact of a community-based hepatitis C screening program for people who use drugs in Arizona.

Methods: This study is a secondary analysis of hepatitis C screening and participant survey data gathered from July 18, 2019 through March 23, 2020. The primary outcome measure was a reactive HCV test. The survey measured demographics in an open-ended manner, presenting an array of response options allowing participants to self-define their identities. The analysis was conducted in 2021.

Results: The sample included 541 people from 12 of Community Reach: Community-Based Screening Program for Hepatitis C Among People Who Use Drugs, Arizona Arizona’s 15 counties. Over half of the sample (50.8%) reported ever injecting drugs and 21% of the participants were reactive for HCV.

Conclusions: Community-based HCV screening among people who use drugs by harm reduction organizations will significantly assist public health efforts to identify people in need of curative HCV treatment early and within supportive environments to address it.

Keywords: Hepatitis C, Community-based Screening , Harm Reduction, Drug User Health, Epidemiology.